Cyanocobalamin
As of the edition of 20 October 2026, Cyanocobalamin is a small molecule: marketed, first approved in 1954 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Rubivite
- First approved
- 5 April 1954 (CH)
- Approvals on record
- 53 in 5 regions
- Holder of the most recent approval
- B. Braun Medical; 24 holders in all
- Registered trials
- 74, 9 stopped early
- Disease areas
- Cancer; Lungs and airways; Nutrition and metabolism; Nervous system; Blood and lymph; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 18 | 13 | 2 | 3 |
| Phase 1 | 7 | 6 | 0 | 0 |
| Phase 2 | 27 | 19 | 1 | 4 |
| Phase 3 | 16 | 12 | 2 | 1 |
| Phase 4 | 6 | 4 | 0 | 1 |
| All trials | 74 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Applicant and Acquired holder | 1954 to now |
| Baxter Healthcare | Later holder | 1987 to now |
| Nastech Pharmaceutical | Later holder | 1996 to now |
| Warner Chilcott | Acquired holder | 2003 to now |
| QOL Medical | Later holder | 2005 to now |
| Merck & Co. | Applicant and Lead sponsor of trials | 2016 to now |
| Endo | Acquired holder | 2024 to now |
| B. Braun Medical | Later holder | 2024 to now |
| Ph Health | Acquired holder | 2025 to now |
| Bel-Mar | Later holder | |
| Bracco Diagnostics | Later holder | |
| Bristol Myers Squibb | Later holder | |
| Pfizer | Later holder |